The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...

Better-than-expected sales of some of its new products, including Skyrizi and Rinvoq, helped AbbVie handle a sharp decline in sales of former cash-cow product Humira in the last quarter of 2023.

AbbVie's positioning in this niche is intact thanks to its superstar products like Rinvoq, Skyrizi, and Humira. Humira has been dominating the space for almost two decades until its patent expired ...

AbbVie (NYSE:ABBV) is navigating significant shareholder activism as it urges opposition to two governance proposals ahead of ...

Right now, Rinvoq is approved in the European Union and the U.S. for the treatment of adults with radiographic axial ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

AbbVie reported better-than-expected fourth-quarter earnings. Strong demand for the company's Skyrizi and Rinvoq autoimmune therapeutics has helped offset the decline in Humira sales since losing ...

Among its best-known products are Humira ... Demand for Skyrizi and Rinvoq boosted the most recent quarterly results. Last month, AbbVie completed its acquisition of Nimble Therapeutics, and ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq ... acquisition of Allergan added several new products and drugs in aesthetics (including ...

While the obesity field is greatly dominated by GLP-1 products, the amylin hormone ... ABBV’s Successful New Drugs — Skyrizi and Rinvoq AbbVie lost patent protection for Humira in the United ...